VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer
Huvudupphovsmän: | , , , , , , , , , , , , , , |
---|---|
Materialtyp: | Conference item |
Publicerad: |
American Society of Clinical Oncology
2018
|
Sammanfattning: |
---|